Defining an extended-spectrum beta-lactamase

Livermore, D. M. ORCID: (2008) Defining an extended-spectrum beta-lactamase. Clinical Microbiology and Infection, 14 (Suppl 1). pp. 3-10. ISSN 1469-0691

Full text not available from this repository. (Request a copy)


The term 'extended-spectrum beta-lactamase' (ESBL), initially 'extended-broad-spectrum beta-lactamase', was first coined for derivatives of TEM and SHV enzymes able to hydrolyse oxyimino-cephalosporins. These all belonged to beta-lactamase functional group 2be. Subsequently, the term has been stretched to include: (i) enzymes with spectra similar to those of TEM and SHV mutants but derived from other sources, e.g., the CTX-M and VEB types; (ii) TEM and SHV mutants with borderline ESBL activity, e.g., TEM-12; and (iii) various beta-lactamases conferring wider resistance than their parent types but not meeting the definition for group 2be, e.g., OXA derivatives and mutant AmpC types with increased activity against cefepime. It seems best-and pragmatic-that the term 'ESBL' retains its broad modern usage, but that should always be accompanied by mention of the enzyme's family as, e.g., in 'TEM ESBL' or 'OXA ESBL', not as a sole moniker.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User: Rhiannon Harvey
Date Deposited: 07 Jul 2011 11:06
Last Modified: 20 Jun 2024 11:30
DOI: 10.1111/j.1469-0691.2007.01857.x

Actions (login required)

View Item View Item